Abstract
Objective
An open pilot study to evaluate the effect of pregabalin (PGB) as add-on therapy on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy (BTRE).
Materials and methods
We recruited 25 consecutive patients with BTRE and uncontrolled seizures. At baseline and during follow-up, patients underwent a complete physical and neurological examination and were evaluated using the QOLIE 31P (V2), EORTC QLQ C30, Adverse Events Profile, and Hamilton Anxiety Rating Scale (HAM-A). At baseline, a seizure diary was given.
Results
During follow-up, 17 patients underwent chemotherapy, none underwent radiotherapy, 9 had disease progression, and 3 died. Mean duration of follow-up was 4.1 months. Mean PGB dosage was 279 mg/day. At baseline, mean weekly seizure frequency was 5.3 (±10) and at last available follow-up visit was 2.8±5. This difference was statistically significant (p=0.016). The responder rate was 76%. Ten patients dropped out; 4 as a result of seizure worsening, 1 as a result of unchanged seizure frequency, 3 as a result of a lack of compliance, and 2 as a result of side effects. Based on the QOLIE-31-P, a significant improvement of the subscale “seizureworry” (p=0.004) and a significant decrease in distress scores related to AEDs and social life (p=0.009 and p=0.008, respectively) were observed. A significant decrease in HAMA score (p=0.002) was documented.
Conclusions
These data indicate that PGB may represent a valid alternative as add-on treatment in this patient population, based on its efficacy on seizure control and anxiety.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Apolone G, Filiberti A, Cifani S, Ruggiata R, Mosconi P. Evaluation of the EORTC QLQ-C30 questionnaire: a comparison with SF-36 Health Survey in a cohort of Italian long-survival cancer patients. Ann Oncol 1998; 9: 549–557.
Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Löscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 2007; 52: 333–346.
Bandelow B, Wedekind D, Leon T. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother 2007; 7: 769–781.
Brodie MJ, Wilson EA, Wesche DL, et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 2005; 46: 1407–1413.
Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events 2003. v4.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev4.pdf
Carreño M, Maestro I, Molins A, et al. Pregabalin as add-on therapy for refractory partial seizures in every day clinical practice. Seizure 2007; 16: 709–712.
Cramer JA, Van Hammée G; N132 Study Group. Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam. Epilepsy Behav 2003; 2: 118–123.
Folstein MF, Folstein SE, McHugh PR. Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–198.
French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003; 60: 1631–1637.
Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects. A randomized trial. Neurology 2004; 62: 23–27.
Giovagnoli AR. Quality of life in patients with stable disease after surgery, radiotherapy, and chemotherapy for malignant brain tumor. J Neurol Neurosurg Psychiatry 1999; 67: 358–363.
Hamilton M. The assessment of anxiety states by rating. Br J Med Psych 1959; 32: 50–55.
Karnofsky DA, Burchenal JH, Armistead GC Jr, et al. Triethylene melamine in the treatment of neoplastic disease. Arch Int Med 1951; 87: 477–516.
Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005; 6: 591–602.
Luna-Tortós C, Fedrowitz M, Löscher W. Several major antiepileptic drugs are substrates for human P glycoprotein. Neuropharmacology 2008; 55: 1364–1375.
Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J 1965; 4: 61–65.
Maschio M, Albani F, Baruzzi A, et al. Levetiracetam therapy in patients with brain tumour and epilepsy. J Neurooncol 2006; 80: 97–100.
Maschio M, Dinapoli L, Zarabla A, et al. Outcome and tolerability of topiramate in brain tumor associated epilepsy. J Neurooncol 2008; 86: 61–70.
Maschio M, Dinapoli L, Vidiri A, et al. The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine. J Exp Clin Cancer Res 2009a; 28: 60.
Maschio M, Dinapoli L, Saveriano F, et al. Efficacy and tolerability of zonisamide as add-on in brain tumorrelated epilepsy: preliminary report. Acta Neurol Scand 2009b; 120: 210–212.
Maschio M, Dinapoli L, Sperati F, et al. Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. J Neurooncol 2011a; 104: 205–214.
Maschio M, Dinapoli L, Mingoia M, et al. Lacosamide as addon in brain tumor-related epilepsy: preliminary report on efficacy and tolerability. J Neurol 2011b; 258: 2100–2104.
Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry 2008; 193: 389–394.
Newton HB, Goldlust SA, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumour patients. J Neurooncol 2005; 78: 99–102.
Ngo L, Nei M, Glass J. Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma. Epilepsia 2006; 47: 1237–1238.
Novy J, Stupp R, Rossetti AO. Pregabalin in patients with primary brain tumours and seizures: a preliminary observation. Clin Neurol Neurosurg 2009; 111: 171–173.
Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. P450 enzyme inducing and nonenzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 2005; 72: 255–260.
Owen RT. Pregabalin: its efficacy, safety and tolerability profile in generalized anxiety. Drugs Today 2007; 43: 601–610.
Pace A, Vidiri A, Galiè E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 2003; 14: 1722–1726.
Perry JR, Sawka C. Add-on gabapentin for refractory seizures in patients with brain tumors. CanJ Neurol Sci 1996; 23: 128–131.
Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2005; 61: 246–255.
Rossetti AO, Stupp R. Epilepsy in brain tumor patients. Curr Opin Neurol 2010; 23: 603–609.
Singh G, Rees JH, Sander JW. Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment. J Neurol Neurosurg Psychiatry 2007; 78: 342–349.
Stein DJ. Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder. Evid Based Ment Health 2007; 10: 23.
Striano S, Striano P, Boccella P, Noverino C, Bilo L. Tiagabine in glial tumors. Epilepsy Res 2002; 49: 81–85.
van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007; 6: 421–430.
Vecht CJ, van Breemen M. Optimizing therapy of seizures in patients with brain tumors. Neurology 2006; 67: S10–S13.
Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003; 2: 404–409.
Wen PY, Marks PW. Medical management of patients with brain tumors. Curr Opin Oncol 2002; 14: 299–307.
Yap KY, Chui WK, Chan A. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther 2008; 30: 1385–1407.
Zung WW. Aself-rating depression scale. ArchGenPsychiatry 1965; 12: 63–70.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Maschio, M., Dinapoli, L., Sperati, F. et al. Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. Epileptic Disord. 14, 388–397 (2012). https://doi.org/10.1684/epd.2012.0542
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1684/epd.2012.0542